Inebilizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Inebilizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target CD19
Clinical data
Synonyms MEDI-551
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6504H10080N1732O2044S44
Molar mass 147 kDa

Inebilizumab (MEDI-551) (INN) is a humanized monoclonal antibody designed for the treatment of cancer, systemic sclerosis and multiple sclerosis.[1][2]

This drug was developed by Cellective Therapeutics, Inc and MedImmune, LLC.

References[edit]